Here is What Institutional Investors Think About Alimera Sciences Inc (NASDAQ:ALIM)

April 20, 2018 - By Ellis Scott

Alimera Sciences, Inc. (NASDAQ:ALIM) Logo

Sentiment for Alimera Sciences Inc (NASDAQ:ALIM)

Alimera Sciences Inc (NASDAQ:ALIM) institutional sentiment decreased to 1 in 2017 Q4. Its down -0.64, from 1.64 in 2017Q3. The ratio has worsened, as 12 investment professionals opened new and increased positions, while 12 decreased and sold their positions in Alimera Sciences Inc. The investment professionals in our partner’s database now have: 28.68 million shares, up from 28.40 million shares in 2017Q3. Also, the number of investment professionals holding Alimera Sciences Inc in their top 10 positions was flat from 0 to 0 for the same number . Sold All: 4 Reduced: 8 Increased: 9 New Position: 3.

Alimera Sciences, Inc., a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. The company has market cap of $79.08 million. It focuses on diseases affecting the back of the eye or retina. It currently has negative earnings. The firm offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema , which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness.

The stock increased 0.89% or $0.01 during the last trading session, reaching $1.13. About 30,140 shares traded. Alimera Sciences, Inc. (NASDAQ:ALIM) has declined 28.28% since April 20, 2017 and is downtrending. It has underperformed by 39.83% the S&P500.

Analysts await Alimera Sciences, Inc. (NASDAQ:ALIM) to report earnings on May, 14. They expect $-0.04 EPS, up 60.00 % or $0.06 from last year’s $-0.1 per share. After $-0.10 actual EPS reported by Alimera Sciences, Inc. for the previous quarter, Wall Street now forecasts -60.00 % EPS growth.

Jw Asset Management Llc holds 1.37% of its portfolio in Alimera Sciences, Inc. for 966,000 shares. Armistice Capital Llc owns 6.81 million shares or 0.9% of their US portfolio. Moreover, Venbio Select Advisor Llc has 0.54% invested in the company for 6.24 million shares. The California-based Acuta Capital Partners Llc has invested 0.24% in the stock. Palo Alto Investors Llc, a California-based fund reported 3.01 million shares.

Since January 1, 0001, it had 1 buy, and 10 selling transactions for $290,803 activity.

Alimera Sciences, Inc. (NASDAQ:ALIM) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.